Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment
Key facts
- Who runs it
- Qilu Hospital of Shandong University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 74 people, planned
- Started
- 10 Sept 2024
- Expected to end
- 30 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- anti-reflux mucosal valvuloplasty (ARMV)
- Record updated
- 18 November 2024
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- 18-60 years of age
- Hiatal hernia ≤ 2 cm
- Sliding hernia ≤ 2 cm
- Recurrence of GERD symptoms after cessation of PPIs
- On daily PPI for ≥1 year or twice daily PPI for at least 8 weeks
- Esophagitis (Los Angeles Classification) Grade B, C, or D
- Hill's flap valve grade ≤ III
- Observation of distal esophageal pH < 4 on at least 1-2 days within a 7-day period, with a percentage exceeding 5.3%
- Normal or near-normal esophageal motility
- Lower esophageal sphincter pressure (LESP) ranging between 5-15 mmHg
- DeMeester score ≥ 14.7 or total reflux episodes exceeding 73
- Completion of a signed informed consent form
Who cannot take part
- History of previous esophageal or gastric surgery, including ARMS or ARMA
- Peptic ulcer disease
- Primary esophageal motility disorders such as achalasia
- Uncontrolled systemic diseases
- BMI > 35 kg/m2
- ASA > II
- Barrett's esophagus
- Hiatal hernia > 2 cm
- Esophagitis (Los Angeles Classification) Grade A or No esophagitis;
- Hill's flap valve grade > III;
- Severe gastroparesis
- Gastric outlet obstruction
- Pregnancy or planning to become pregnant
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study objective is to evaluate the relative merits, safety and effectiveness of Anti-reflux mucosal valvuloplasty (ARMV) in GERD patients currently treated with daily Proton Pump Inhibitors (PPIs).
The 2 groups in the trial
- ARMV (intervention group)Treatment being tested
Under general anesthesia, patients are positioned in the left lateral decubitus position and undergo endoscopic examination of the esophagus and stomach. The surgery utilizes a single-channel gastroscope (EG29-i10, Pentax, Japan, or GIF-H290T, Olympus, Japan) and a high-frequency generator (VIO300D, Erbe, Germany). A transparent cap (D-201, Olympus, Japan) is attached to the gastroscope to improve visualization and aid in manipulating the flap valve. The DualKnife (Olympus, Japan) is selected for dissection due to its maneuverability in a retroflexed fashion. For patients with esophageal strictures obstructing scope passage, esophageal dilation is performed using Savary-Gilliard dilators (Cook Medical, USA) just before ARMV.
Treatment: anti-reflux mucosal valvuloplasty (ARMV)
- PPI (control group)No study treatment, for comparison
Patients randomized to the PPI group will follow the PPI treatment scheme. If GERD symptoms are effectively controlled with their current PPI dosage for at least one month, the regimen is decreased by one step. Conversely, if symptoms are poorly controlled, the dosage is increased by one step based on the PPI algorithm, which aligns with best clinical practices. The use of PPI will be recorded in medication diaries using generic names listed in the table below and classified according to the daily dose and frequency. Dosage will be categorized as "double dose" = ≥30 or 40 mg per day, "full dose" = 30 or 40 mg per day, "half dose" = 15 or 20 mg per day, "occasional" or "on demand" = \< "full dose" taken for \< 50% of days in the follow-up period. Common medications include Nexium 20mg、Prevacid 30mg、Prilosec 20mg、Protonix 20mg、Aciphex20mg.The frequency of medication use is once a day.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Anti-reflux Mucosal Valvuloplasty Versus Proton Pump Inhibitors for the Treatment of Patients With Gastroesophageal Reflux Disease in a Tertiary Healthcare Center in China: Study Protocol for a Randomized Controlled Trial
- Criteria questions
- Built from NCT06348420, who can take part
- Publications
- Record updated
- 18 November 2024